A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Relapse in Patients With IBD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-28

Study Completion Date

2021-01-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition of the intestine, which results in diarrhea, rectal bleeding, urgency, weight loss and abdominal pain. The natural course of IBD is characterized by activity outbreaks and periods of remission. In most cases, relapses in Crohn's disease (CD) and in ulcerative colitis (UC) are unpredictable and despite effective medical treatment, a degree of subclinical inflammation may persist in the bowel wall, contributing to a significant risk of relapse.

In IBD, altered fecal microbiota signatures have been consistently reported which included a reduction in biodiversity with lower proportions of Firmicutes and increases in Proteobacteria and Bacteroidetes phylum members.

It is however unclear whether changes in microbial profile including diversity and composition can predict disease relapse in IBD. We hypothesize that fecal microbial signatures in conjunction with fecal calprotectin may play a role in predicting relapse in IBD patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of Novel Fecal Microbial Biomarkers for Inflammatory Bowel Disease

NCT05598489

Inflammatory Bowel Diseases Ulcerative Colitis Crohn Disease +1 more

UNKNOWN

Gut Microbiota in the Healthy Population, Inflammatory Bowel Disease Patients, and Their Relatives

NCT01140802

Inflammatory Bowel Disease

TERMINATED

Bacterial Transmission In Utero and IBD Risk

NCT03116568

IBD Pregnancy Related Microbiota

ACTIVE_NOT_RECRUITING

A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Response to Biological Therapy in Patients With CD

NCT03994224

Crohn Disease Perianal Crohn Disease

TERMINATED

Remote Monitoring of IBD

NCT05886322

Inflammatory Bowel Diseases Crohn Disease Ulcerative Colitis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition of the intestine, which results in diarrhea, rectal bleeding, urgency, weight loss and abdominal pain. The natural course of IBD is characterized by activity outbreaks and periods of remission. In most cases, relapses in Crohn's disease (CD) and in ulcerative colitis (UC) are unpredictable and despite effective medical treatment, a degree of subclinical inflammation may persist in the bowel wall, contributing to a significant risk of relapse.

Endoscopy has been used to monitor a disease but it is time-consuming, costly, invasive, and associated with certain risks of morbidity. Many patients are reluctant to undergo repeated endoscopic examinations, particularly when their disease is quiescent. Acute phase reactants have been used but their sensitivity and specificity in correlating to intestinal inflammatory activity are very low, and their capacity to predict disease relapse is poor and controversial. A number of fecal biomarkers have been evaluated for their utility for monitoring and predicting relapse in IBD but some of these biomarkers are also not specific.

In IBD, altered fecal microbiota signatures have been consistently reported which included a reduction in biodiversity with lower proportions of Firmicutes and increases in Proteobacteria and Bacteroidetes phylum members. In addition, disease remission and relapse are associated with microbial changes in both mucosal and fecal samples. In particular, a loss of species richness in Crohn's disease has been widely observed. Recently microbial biomarkers may differentiate between CD and UC. Furthermore, different microbial groups are associated with smoking habit and localization of the disease in CD and UC. It is however unclear whether changes in microbial profile including diversity and composition can predict disease relapse in IBD. We hypothesize that fecal microbial signatures in conjunction with fecal calprotectin may play a role in predicting relapse in IBD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases Ulcerative Colitis Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient with Crohn's Disease

1. Aged ≥18 years old
2. Confirmed diagnosis of ileo-colonic Crohn's disease according to established clinical, endoscopic and histologic criteria
3. History of at least one flare with symptoms that required intervention within 24 months before screening
4. Stable doses of immunosuppressive agents for at least 3 months if these agents are required
5. In clinical remission for at least 3 months, defined as Harvey Bradshaw Index (HBI) score \< 4
6. Written informed consent obtained

Patient with Ulcerative Colitis

1. Aged ≥18 years old
2. Have a confirmed diagnosis of ulcerative colitis according to established clinical, endoscopic and histologic criteria
3. History of at least one flare with symptoms that required intervention within 24 months before screening
4. On stable regimen of 5-ASA for at least 3 months
5. In clinical remission for at least 3 months defined as partial Mayo score ≤ 1
6. Written informed consent obtained

Exclusion Criteria

1. Previous bowel surgery /stoma
2. On anti-TNF therapy
3. Malignant disease within 5 years
4. Use of probiotics, prebiotics or antibiotics in past 3 months
5. Terminal illness

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No